


Antiretroviral Discovery, Evaluation and Application Research (ADEAR) Training Program
University of Colorado Anschutz Medical Campus

The **ADEAR Training Program** is now accepting applications for post-doctoral training in HIV/AIDS-related research. This integrative program provides multidisciplinary training in basic, translational and clinical science in human immunodeficiency virus type 1 (HIV)/Acquired Immunodeficiency Syndrome (AIDS) research. Awardees will receive training under the direction of a broadly based group of faculty at the University of Colorado campuses in Aurora, Boulder and Denver, Colorado State University and Denver University. Our training program faculty are experienced mentors and actively engaged in research spanning basic virology, drug development, medication adherence, treatment of comorbidities, PrEP, STDs, TB, development of new models of care, and HIV in resource-limited settings. Information about the participating institutions is available at the following websites:
https://www.cuanschutz.edu/
https://www.colostate.edu/
https://www.colorado.edu/
https://www.ucdenver.edu/
https://www.du.edu/

Trainees receive salary and benefits support according to NIH guidelines, travel funds, and funds to pay for training-related coursework. Support is typically provided for two years, contingent on progress in the first year. One additional year of support can be requested at the end of year two. Award of a third year of support is contingent on approval of the Training Program Steering Committee.

All applicants must:

- Hold a terminal degree in their field (e.g., D.D.S, D.O., D.N.P., D.V.M., M.D., Pharm.D. and/or Ph.D.)
- Be a *U.S. citizen or a permanent U.S. resident* "Green Card" holder
- Be committed to a career as an investigator in HIV-related research
- Be able to devote full-time effort to the training program during the period of support.
- The applicant's mentor has to be a full-time faculty at one of the above mentioned institutions and hold an R01 or equivalent funding during the training period.

General instructions, criteria, and selection process:

- Please refer to the NIH web site for specific Institutional NRSA (T32) details and requirements (https://researchtraining.nih.gov/programs/training-grants/T32). All candidates must agree to applicable payback stipulations in the T32 regulations.
- All candidates should have completed their terminal degree by the start of T32 support, have not received independent funding, and have a proposed mentored research project related to

HIV/AIDS. Preference will be given to applications broadly related to HIV treatment (from basic science to clinical dissemination/implementation). Interested applicants without an identified mentor or project are encouraged to reach out to T32 faculty members or T32 leadership to develop a proposal.

- All recipients will be encouraged to submit at least one additional grant during the funding cycle.
- All candidates doing human subject research are required to have passed the NIH required human subjects training and test (CITI Basic www.citiprogram.org), and have approval from the IRB and CTRC (if appropriate) before initiating the research.
- All candidates are expected to include appropriate (recently revised) training in responsible conduct of research per NIH Grants Policy Statement (see below).
- Co-mentoring between senior and junior level faculty is encouraged.
- Underrepresented minority, disabled, or disadvantaged candidates are especially encouraged to apply.
- All proposals should relate to the high priority topics for HIV/AIDS research (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html)

Application Instructions:

- Applications, which include the following documents, must be submitted electronically through the program website linked below. Please contact Kelly Rico, ADEAR Program Administrator, at kelly.rico@cuanschutz.edu with any questions.

  Apply here

1. Letter of interest from candidate, including statement of interest in academic career and commitment to pursuing a career in HIV-related research, and training plan during the proposed 2-year funding period. **Limit 2 pages**.
2. CV, resume, or NIH biosketch of the applicant.
3. NIH biosketch of the mentor including the current funding.
4. Letters of recommendations (4 total) including 1 from proposed postdoctoral mentors (combined if co-mentors) for the proposed training project.
5. Career Development Plan (Limit 1 page).
6. Project description from candidate (font Arial 11, ½" margins). **Limit 3 pages**
    a. Specific aims/hypotheses
    b. Background
    c. Brief experimental approach
    d. Brief Timeline for research activity and expected end products of your research (spanning 2 possible years of funding)
7. References (Limit 1 page, not inclusive of project description)
8. Training Responsible Conduct of Research (for specific requirements see: https://www.niaid.nih.gov/research/responsible-conduct-research-training) **Limit 1 page**
    a. Format: must include face-to-face (via zoom or in person depending on the institutional guidelines) discussions among trainees (case studies).
    b. Subject Matter
    c. Faculty Participation: training faculty are highly encouraged to participate in formal/informal instruction.
    d. Duration of Instruction: at least 8 contact hours of instruction (semester-long series are preferred).
    e. Frequency of Instruction: at least once in each career stage and/or every 4 years.

Awards:

- The NIH study section format will be used to rank the applications.

T32 ADEAR Faculty

*Note to Prospective Applicants: please feel free to contact our training faculty for potential fellowship opportunities in their respective laboratories.

T32 Faculty		Research Interests	Contact Info
	**Thomas Campbell, M.D.** Co-Program Director Professor of Medicine and Microbiology UC-AMC	Clinical investigations of antiretrovirals for treating HIV/AIDS	Email: THOMAS.CAMPBELL@CUANSCHUTZ.EDU Faculty Website
	**Mamuka Kvaratskhelia, Ph.D.** Co-Program Director Professor, Division of Infectious Diseases UC-AMC	HIV integrase and capsid inhibitors.	Email: MAMUKA.KVARATSKHELIA@CUANSCHUTZ.EDU Faculty Website
	**Kristine Erlandson, M.D.** Associate Program Director Associate Professor of Medicine, Division of Infectious Diseases UC-AMC	Improving the health and quality of life of older adults aging with HIV.	Email: KRISTINE.ERLANDSON@CUANSCHUTZ.EDU Faculty Website
	**Lisa Abuogi, M.D.** Assistant Professor of Pediatrics, Section of Infectious Diseases UC-AMC	Implementation science to improve HIV prevention and treatment in resource limited settings.	Email: Lisa.Abuogi@childrenscolorado.org Faculty Website
	**Ramesh Akkina, Ph.D.** Professor of Microbiology, Immunology and Pathology CSU	Humanized mouse models for evaluation of new approaches to HIV treatment and prevention.	Email: Ramesh.Akkina@colostate.edu Faculty Website

	**Peter Anderson, Pharm.D.** Professor of Pharmaceutical Sciences UC-AMC	Clinical pharmacology of antiretroviral agents.	Email: PETER.ANDERSON@CUANSCHUTZ.EDU Faculty Website
	**Jose Castillo-Mancilla, M.D.** Associate Professor of Medicine, Division of Infectious Diseases UC-AMC	Applied antiretroviral clinical pharmacology with emphasis on antiretroviral drug adherence, optimization of current antiretroviral therapies, pharmacogenomics and pre-exposure prophylaxis (PrEP).	Email: JOSE.CASTILLO-MANCILLA@CUANSCHUTZ.EDU Faculty Website
	**Chaoping Chen, Ph.D.** Associate Professor of Biochemistry and Molecular Biology CSU	Cell-based assay to study autoprocessing of HIV protease precursors as a rapid tool for phenotype assessment to evaluate the effects of mutations outside of the protease coding region on protease phenotype.	Email: Chaoping.Chen@colostate.edu Faculty Website
	**Christopher DeSouza, Ph.D.** Professor of Integrative Physiology UCB	Regulation of endothelial vasomotor regulation; endothelial fibrinolytic control; plasma proteomic markers of endothelial function; endothelial progenitor cell function; and the effects of exercise and antioxidant supplementation on endothelial health and function.	Email: desouzac@colorado.edu Faculty Website

	**Edward N. Janoff, M.D.** Professor of Medicine, Division of Infectious Diseases UC-AMC	Induction of systemic and mucosal responses to Streptococcus pneumoniae infection and vaccination during antiretroviral therapy, the molecular basis for capsule-specific antibody responses (VH gene diversity and mutational pattern), and the functional activity of these human antibodies.	Email: EDWARD.JANOFF@CUANSCHUTZ.EDU Faculty Website
	**Jennifer Kiser, Pharm.D.** Associate Professor of Pharmaceutical Sciences UC-AMC	Intracellular pharmacology of nucleos(t)ide analogs, drug interactions with antiviral therapies, pharmacokinetics of antivirals in patients with viral hepatitis and special populations with HIV (pregnant women, children, those coinfected with viral hepatitis), and effects of recreational drug use on antiviral pharmacology and adherence.	Email: JENNIFER.KISER@CUANSCHUTZ.EDU Faculty Website
	**Laurel Lenz, Ph.D.** Professor of Immunology and Microbiology UC-AMC	Better-understanding of how innate immune responses are regulated and dysregulated in the context of health and disease.	Email: LAUREL.LENZ@CUANSCHUTZ.EDU Faculty Website
	**Myron J. Levin, M.D.** Professor of Pediatrics and Medicine, Section of Infectious Diseases UC-AMC	Antiviral therapy in children, adolescents and pregnant women and in especially the immunology of vaccines.	Email: MYRON.LEVIN@CUANSCHUTZ.EDU Faculty Website

	**Catherine Lozupone, Ph.D.** Assistant Professor of Medicine, Division of Bioinformatics and Personalized Medicine UC-AMC	Factors that shape human microbiome composition in health and disease and investigates the functional consequences of compositional differences, both in terms of the biological/metabolic properties of individual bacteria and host interactions.	Email: CATHERINE.LOZUPONE@CUANSCHUTZ.EDU Faculty Website
	**Elizabeth McFarland, M.D.** Professor of Pediatrics, Head, Section of Infectious Diseases UC-AMC	Maturation of cell-mediated immune responses in both HIV-exposed and HIV-infected infants, immune responses to HIV vaccines in HIV-exposed newborns, the role of cytotoxic T-lymphocytes in the pathogenesis of congenitally acquired HIV infection, pediatric HIV clinical trials of antiretroviral therapy and vaccines.	Email: BETSY.MCFARLAND@CUANSCHUTZ.EDU Faculty Website
	**Brent Palmer, Ph.D.** Associate Professor of Medicine, Division of Allergy and Clinical Immunology UC-AMC	Effects of HIV infection on systemic and mucosal immunity and interactions between commensal microbiota in the gut and lung and the immune system during antiretroviral therapy.	Email: BRENT.PALMER@CUANSCHUTZ.EDU Faculty Website
	**Eric Poeschla, M.D.** Professor of Medicine, Head, Division of Infectious Diseases UC-AMC	Basic aspects of retroviral replication, host innate immunity to retroviruses, and retroviral disease pathogenesis including host cell dependency factors,	Email: ERIC.POESCHLA@CUANSCHUTZ.EDU Faculty Website

		cell-intrinsic innate immunity/restriction factors, integration, and accessory protein function.	
	**Mario Santiago, Ph.D.** Associate Professor of Medicine, Division of Infectious Diseases UC-AMC	Defining innate antiretroviral mechanisms and their impact on humoral and cell-mediated immune responses in vivo, using three complementary biological systems.	Email: MARIO.SANTIAGO@CUANSCHUTZ.EDU Faculty Website
	**Sarah Sawyer, Ph.D.** Associate Professor of Molecular, Cellular and Developmental Biology UCB	Viral restriction factors and viral entry receptors by combining laboratory research in virology with tools from molecular evolution, population genetics, bioinformatics, and genomics.	Email: ssawyer@Colorado.EDU Faculty Website
	**Raul Torres, Ph.D.** Professor of Immunology and Microbiology UC-AMC	Understanding how the distinct B cell populations that exist in humans and mice act in concert to provide humoral immunity including the contribution of marginal zone B cells to the antibody response to HIV.	Email: RAUL.TORRES@CUANSCHUTZ.EDU Faculty Website
	**Linda van Dyk, Ph.D.** Professor Immunology and Microbiology UC-AMC	Characterization of host-pathogen interactions in gammaherpesvirus infection, with primary emphasis on latency and reactivation.	Email: LINDA.VANDYK@CUANSCHUTZ.EDU Faculty Website

	**Schuyler Van Engelenburg, Ph.D.** Assistant Professor of Biological Sciences DU	Researching the mechanisms of viral biogenesis and educating the next generation of virologists and cellular biophysicits.	Email: schuyler.vanengelenburg@du.edu Faculty Website
	**Adriana Weinberg, M.D.** Professor of Pediatrics and Medicine, Section of Infectious Diseases UC-AMC	Evaluating immune restoration in antiretroviral therapy.	Email: ADRIANA.WEINBERG@CUANSCHUTZ.EDU Faculty Website
	**Cara Wilson, M.D.** Professor of Medicine, Division of Infectious Diseases UC-AMC	Investigating the role of dendritic cells and HIV-specific T cells in the control of HIV replication.	Email: CARA.WILSON@CUANSCHUTZ.EDU Faculty Website